Patients

Neomorph is currently conducting a clinical trial, NEO-811-101, an open-label, first-in-human, Phase 1/2 dose escalation and expansion study of NEO-811 for participants with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The purpose of this clinical research study is to test the safety of the investigational study drug NEO-811 at different doses, to understand the way the body processes and responds to NEO-811, and to find out what effects NEO-811 may have on kidney cancer. To learn more about this trial, including eligibility criteria and study locations, please visit ClinicalTrials.gov.